Bodyport

Executive Summary

Bodyport is a biomarker-guided digital therapeutics company based in San Francisco, founded in 2015. The company focuses on cardiovascular health by embedding a sophisticated biomarker platform into simple, easy-to-use home devices. Their flagship product enables individuals to monitor heart health with one simple step, providing comprehensive health insights. Bodyport aims to address complex chronic conditions through digital interventions, leveraging biomarkers to guide therapy. While the company operates in the growing digital health space, specific details on funding, revenue, and clinical validation are limited. However, its focus on cardiovascular disease—a leading cause of death—positions it in a large market. The company likely requires regulatory clearances and clinical data to gain traction.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance or CE Mark for Digital Therapeutic Platform60% success
• Q2 2027Publication of Clinical Trial Results Demonstrating Efficacy50% success
• Q3 2026Strategic Partnership with a Major Healthcare Provider or Pharma Company40% success